Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX) is -36.83% lower on its value in year-to-date trading and has touched a low of $6.15 and a high of $22.11 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The CPRX stock was last observed hovering at around $12.08 in the last trading session, with the day’s loss setting it -0.33% off its average median price target of $22.00 for the next 12 months. It is also 53.0% off the consensus price target high of $25.00 offered by 5 analysts, but current levels are 21.67% higher than the price target low of $15.00 for the same period.
Currently trading at $11.75, the stock is -21.32% and -26.40% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.91 million and changing -2.73% at the moment leaves the stock -24.09% off its SMA200. CPRX registered 69.80% gain for a year compared to 6-month gain of -24.49%. The firm has a 50-day simple moving average (SMA 50) of $4.41 and a 200-day simple moving average (SMA200) of $8.84.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
Sponsored
The stock witnessed a -26.97% loss in the last 1 month and extending the period to 3 months gives it a -23.10%, and is -6.23% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.49% over the week and 5.04% over the month.
Catalyst Pharmaceuticals Inc. (CPRX) has around 82 employees, a market worth around $1.25B and $256.50M in sales. Current P/E ratio is 13.31 and Fwd P/E is 8.10. Profit margin for the company is 38.80%. Distance from 52-week low is 91.06% and -46.86% from its 52-week high. The company has generated returns on investments over the last 12 months (26.70%).
Catalyst Pharmaceuticals Inc. (CPRX) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Catalyst Pharmaceuticals Inc. (CPRX) is a “Buy”. 5 analysts offering their recommendations for the stock have an average rating of 2.20, where 1 rate it as a Hold and 0 think it is a “Overweight”. 4 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Catalyst Pharmaceuticals Inc. is expected to release its quarterly report on 08/08/2023.The EPS is expected to grow by 103.70% this year
Catalyst Pharmaceuticals Inc. (CPRX) Top Institutional Holders
The shares outstanding are 105.56M, and float is at 97.66M with Short Float at 11.46%.
Catalyst Pharmaceuticals Inc. (CPRX) Insider Activity
A total of 56 insider transactions have happened at Catalyst Pharmaceuticals Inc. (CPRX) in the last six months, with sales accounting for 23 and purchases happening 33 times. The most recent transaction is an insider sale by MCENANY PATRICK J, the company’s President and CEO. SEC filings show that MCENANY PATRICK J sold 26,151 shares of the company’s common stock on May 15 at a price of $13.23 per share for a total of $0.35 million. Following the sale, the insider now owns 3.95 million shares.
Catalyst Pharmaceuticals Inc. disclosed in a document filed with the SEC on Apr 05 that Tierney David S (Director) sold a total of 30,000 shares of the company’s common stock. The trade occurred on Apr 05 and was made at $16.83 per share for $0.5 million. Following the transaction, the insider now directly holds 0.31 million shares of the CPRX stock.
Still, SEC filings show that on Mar 29, GRANDE ALICIA (VP, Treasurer and CFO) disposed off 50,000 shares at an average price of $16.70 for $0.84 million. The insider now directly holds 50,557 shares of Catalyst Pharmaceuticals Inc. (CPRX).
Catalyst Pharmaceuticals Inc. (CPRX): Who are the competitors?
The company’s main competitors (and peers) include Johnson & Johnson (JNJ) that is trading -12.70% down over the past 12 months and Pfizer Inc. (PFE) that is -26.95% lower over the same period. Abbott Laboratories (ABT) is -9.55% down on the 1-year trading charts.
